NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors

Brian A. McCarthy, Liqun Yang, Jane Ding, Mingqiang Ren, William King, Mohammed Elsayed Elsalanty, Ibrahim Zakhary, Mohamed M.H. Sharawy, Hongjuan Cui, Hanfei Ding

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Abnormal NF-κB2 activation has been implicated in the pathogenesis of multiple myeloma, a cancer of plasma cells. However, a causal role for aberrant NF-κB2 signaling in the development of plasma cell tumors has not been established. Also unclear is the molecular mechanism that drives the tumorigenic process. We investigated these questions by using a transgenic mouse model with lymphocyte-targeted expression of p80HT, a lymphoma-associated NF-κB2 mutant, and human multiple myeloma cell lines.Methods: We conducted a detailed histopathological characterization of lymphomas developed in p80HT transgenic mice and microarray gene expression profiling of p80HT B cells with the goal of identifying genes that drive plasma cell tumor development. We further verified the significance of our findings in human multiple myeloma cell lines.Results: Approximately 40% of p80HT mice showed elevated levels of monoclonal immunoglobulin (M-protein) in the serum and developed plasma cell tumors. Some of these mice displayed key features of human multiple myeloma with accumulation of plasma cells in the bone marrow, osteolytic bone lesions and/or diffuse osteoporosis. Gene expression profiling of B cells from M-protein-positive p80HT mice revealed aberrant expression of genes known to be important in the pathogenesis of multiple myeloma, including cyclin D1, cyclin D2, Blimp1, survivin, IL-10 and IL-15. In vitro assays demonstrated a critical role of Stat3, a key downstream component of IL-10 signaling, in the survival of human multiple myeloma cells.Conclusions: These findings provide a mouse model for human multiple myeloma with aberrant NF-κB2 activation and suggest a molecular mechanism for NF-κB2 signaling in the pathogenesis of plasma cell tumors by coordinated regulation of plasma cell generation, proliferation and survival.

Original languageEnglish (US)
Article number203
JournalBMC Cancer
Volume12
DOIs
StatePublished - May 29 2012

Fingerprint

Plasmacytoma
Multiple Myeloma
Mutation
Survival
Plasma Cells
Gene Expression Profiling
Interleukin-10
Transgenic Mice
Lymphoma
B-Lymphocytes
Cyclin D2
Cell Line
Interleukin-15
Cyclin D1
Osteoporosis
Immunoglobulin M
Blood Proteins
Cell Survival
Bone Marrow
Cell Proliferation

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors. / McCarthy, Brian A.; Yang, Liqun; Ding, Jane; Ren, Mingqiang; King, William; Elsalanty, Mohammed Elsayed; Zakhary, Ibrahim; Sharawy, Mohamed M.H.; Cui, Hongjuan; Ding, Hanfei.

In: BMC Cancer, Vol. 12, 203, 29.05.2012.

Research output: Contribution to journalArticle

McCarthy, Brian A. ; Yang, Liqun ; Ding, Jane ; Ren, Mingqiang ; King, William ; Elsalanty, Mohammed Elsayed ; Zakhary, Ibrahim ; Sharawy, Mohamed M.H. ; Cui, Hongjuan ; Ding, Hanfei. / NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors. In: BMC Cancer. 2012 ; Vol. 12.
@article{6416c29dc8214fafbb6edc0bd7542aa5,
title = "NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors",
abstract = "Background: Abnormal NF-κB2 activation has been implicated in the pathogenesis of multiple myeloma, a cancer of plasma cells. However, a causal role for aberrant NF-κB2 signaling in the development of plasma cell tumors has not been established. Also unclear is the molecular mechanism that drives the tumorigenic process. We investigated these questions by using a transgenic mouse model with lymphocyte-targeted expression of p80HT, a lymphoma-associated NF-κB2 mutant, and human multiple myeloma cell lines.Methods: We conducted a detailed histopathological characterization of lymphomas developed in p80HT transgenic mice and microarray gene expression profiling of p80HT B cells with the goal of identifying genes that drive plasma cell tumor development. We further verified the significance of our findings in human multiple myeloma cell lines.Results: Approximately 40{\%} of p80HT mice showed elevated levels of monoclonal immunoglobulin (M-protein) in the serum and developed plasma cell tumors. Some of these mice displayed key features of human multiple myeloma with accumulation of plasma cells in the bone marrow, osteolytic bone lesions and/or diffuse osteoporosis. Gene expression profiling of B cells from M-protein-positive p80HT mice revealed aberrant expression of genes known to be important in the pathogenesis of multiple myeloma, including cyclin D1, cyclin D2, Blimp1, survivin, IL-10 and IL-15. In vitro assays demonstrated a critical role of Stat3, a key downstream component of IL-10 signaling, in the survival of human multiple myeloma cells.Conclusions: These findings provide a mouse model for human multiple myeloma with aberrant NF-κB2 activation and suggest a molecular mechanism for NF-κB2 signaling in the pathogenesis of plasma cell tumors by coordinated regulation of plasma cell generation, proliferation and survival.",
author = "McCarthy, {Brian A.} and Liqun Yang and Jane Ding and Mingqiang Ren and William King and Elsalanty, {Mohammed Elsayed} and Ibrahim Zakhary and Sharawy, {Mohamed M.H.} and Hongjuan Cui and Hanfei Ding",
year = "2012",
month = "5",
day = "29",
doi = "10.1186/1471-2407-12-203",
language = "English (US)",
volume = "12",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors

AU - McCarthy, Brian A.

AU - Yang, Liqun

AU - Ding, Jane

AU - Ren, Mingqiang

AU - King, William

AU - Elsalanty, Mohammed Elsayed

AU - Zakhary, Ibrahim

AU - Sharawy, Mohamed M.H.

AU - Cui, Hongjuan

AU - Ding, Hanfei

PY - 2012/5/29

Y1 - 2012/5/29

N2 - Background: Abnormal NF-κB2 activation has been implicated in the pathogenesis of multiple myeloma, a cancer of plasma cells. However, a causal role for aberrant NF-κB2 signaling in the development of plasma cell tumors has not been established. Also unclear is the molecular mechanism that drives the tumorigenic process. We investigated these questions by using a transgenic mouse model with lymphocyte-targeted expression of p80HT, a lymphoma-associated NF-κB2 mutant, and human multiple myeloma cell lines.Methods: We conducted a detailed histopathological characterization of lymphomas developed in p80HT transgenic mice and microarray gene expression profiling of p80HT B cells with the goal of identifying genes that drive plasma cell tumor development. We further verified the significance of our findings in human multiple myeloma cell lines.Results: Approximately 40% of p80HT mice showed elevated levels of monoclonal immunoglobulin (M-protein) in the serum and developed plasma cell tumors. Some of these mice displayed key features of human multiple myeloma with accumulation of plasma cells in the bone marrow, osteolytic bone lesions and/or diffuse osteoporosis. Gene expression profiling of B cells from M-protein-positive p80HT mice revealed aberrant expression of genes known to be important in the pathogenesis of multiple myeloma, including cyclin D1, cyclin D2, Blimp1, survivin, IL-10 and IL-15. In vitro assays demonstrated a critical role of Stat3, a key downstream component of IL-10 signaling, in the survival of human multiple myeloma cells.Conclusions: These findings provide a mouse model for human multiple myeloma with aberrant NF-κB2 activation and suggest a molecular mechanism for NF-κB2 signaling in the pathogenesis of plasma cell tumors by coordinated regulation of plasma cell generation, proliferation and survival.

AB - Background: Abnormal NF-κB2 activation has been implicated in the pathogenesis of multiple myeloma, a cancer of plasma cells. However, a causal role for aberrant NF-κB2 signaling in the development of plasma cell tumors has not been established. Also unclear is the molecular mechanism that drives the tumorigenic process. We investigated these questions by using a transgenic mouse model with lymphocyte-targeted expression of p80HT, a lymphoma-associated NF-κB2 mutant, and human multiple myeloma cell lines.Methods: We conducted a detailed histopathological characterization of lymphomas developed in p80HT transgenic mice and microarray gene expression profiling of p80HT B cells with the goal of identifying genes that drive plasma cell tumor development. We further verified the significance of our findings in human multiple myeloma cell lines.Results: Approximately 40% of p80HT mice showed elevated levels of monoclonal immunoglobulin (M-protein) in the serum and developed plasma cell tumors. Some of these mice displayed key features of human multiple myeloma with accumulation of plasma cells in the bone marrow, osteolytic bone lesions and/or diffuse osteoporosis. Gene expression profiling of B cells from M-protein-positive p80HT mice revealed aberrant expression of genes known to be important in the pathogenesis of multiple myeloma, including cyclin D1, cyclin D2, Blimp1, survivin, IL-10 and IL-15. In vitro assays demonstrated a critical role of Stat3, a key downstream component of IL-10 signaling, in the survival of human multiple myeloma cells.Conclusions: These findings provide a mouse model for human multiple myeloma with aberrant NF-κB2 activation and suggest a molecular mechanism for NF-κB2 signaling in the pathogenesis of plasma cell tumors by coordinated regulation of plasma cell generation, proliferation and survival.

UR - http://www.scopus.com/inward/record.url?scp=84861468201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861468201&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-12-203

DO - 10.1186/1471-2407-12-203

M3 - Article

C2 - 22642622

AN - SCOPUS:84861468201

VL - 12

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 203

ER -